Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8956248 | Hematology/Oncology and Stem Cell Therapy | 2018 | 5 Pages |
Abstract
Patients with CHD-both cyanotic and acyanotic-have variable degrees of increased liability for both thrombosis and hemorrhage that represents some sort of adaptation to preserve hemostasis and to protect these patients against the clinical presentation of both thrombosis and bleeding. This is to say that CHD patients have their own point of balance between thrombogenicity and bleeding liability. Wide-scale studies are needed to detect the normal levels of different thrombohemorrhagic parameters of these patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Shebl Said Shebl, Walid Ahmed Naguib El-shehaby, Yasmin Shebl Said, Amira Hamed Darwish, Nabeh Helal Elfadaly, Eman Amer,